Apellis Pharmaceuticals expects European regulators to reject eye disease drug
Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares fell more than 22% after it said it expects European regulators to reject its therapeutic…
0,138€
0,88%
Echtzeit-Aktienkurs Pieris Pharmaceuticals
Bid:
Ask:
Nachrichten zur Pieris Pharmaceuticals Aktie
: Apellis Pharmaceuticals shares rally as competing eye treatment fails to impress analysts
Apellis Pharmaceuticals Inc. shares APLS jumped 8% premarket on Tuesday after competitor Iveric Bio, a unit of Astellas Pharma Inc.…
Form 10-Q PIERIS PHARMACEUTICALS, For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
XFRA : PI6: Aussetzung/Suspension
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME …
Pieris Pharma Shares Surge After Restructuring, Job Cuts
Pieris Pharma Shares Surge After Restructuring, Job Cuts...…
Pieris Pharma to Cut 70% of Workforce, Explore Strategic Options
Pieris Pharma to Cut 70% of Workforce, Explore Strategic Options...…
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
BOSTON, MA / ACCESSWIRE / July 18, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics…
XFRA : INSTRUMENT_SUSPENSION - US7207951036
Instrument ID [10029] (PI6 - US7207951036) suspended...…
Form 8-K PIERIS PHARMACEUTICALS, For: Jul 17
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K PIERIS PHARMACEUTICALS, For: Jul 13
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K PIERIS PHARMACEUTICALS, For: Jun 21
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Pieris Pharma Shares Drop in Premarket Trading as Partner Ends Asthma Treatment Trials
Pieris Pharma Shares Drop in Premarket Trading as Partner Ends Asthma Treatment Trials...…
Pieris Pharma Shares Halted as Partner Discontinues Asthma Treatment Trial
Pieris Pharma Shares Halted as Partner Discontinues Asthma Treatment Trial...…
XFRA : INSTRUMENT_SUSPENSION - US7207951036
Instrument ID [10029] (PI6 - US7207951036) suspended...…
Form 8-K PIERIS PHARMACEUTICALS, For: Jun 21
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
BOSTON, MA / ACCESSWIRE / June 21, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics…
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics…
Insiderhandel: Aufsichtsrat kauft Aktien von Pieris Pharmaceuticals im Wert von 8.500$
Kiritsy, Christopher P. - Aufsichtsrat - Tag der Transaktion: 2023-05-25...…
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
BOSTON, MA / ACCESSWIRE / May 21, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics…
Pieris Pharmaceuticals: Q1 Earnings Insights
read more...…
Form 8-K PIERIS PHARMACEUTICALS, For: May 10
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MAY 10, 2023, AT 8:00 AM EDTEnrollment for elarekibep (PRS-060/AZD1402) Phase…
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
BOSTON, MA / ACCESSWIRE / May 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics…
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa At 2023 AACR Annual Meeting
BOSTON, MA / ACCESSWIRE / April 17, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics…
Form 8-K PIERIS PHARMACEUTICALS, For: Mar 29
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Pieris Pharmaceuticals GAAP EPS of -$0.45 beats by $0.02, revenue of $25.9M misses by $0.67M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Pieris Pharmaceuticals Q4 2022 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023
BOSTON, MA / ACCESSWIRE / March 24, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS),a clinical-stage biotechnology company advancing novel biotherapeutics through…
Form 8-K PIERIS PHARMACEUTICALS, For: Jan 10
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K PIERIS PHARMACEUTICALS, For: Nov 04
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-Q PIERIS PHARMACEUTICALS, For: Sep 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 18.75% and 19.04%, respectively, for the quarter ended September 2022. Do…
Pieris Pharmaceuticals GAAP EPS of -$0.13 in-line, revenue of $5.37M beats by $0.86M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K PIERIS PHARMACEUTICALS, For: Nov 01
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…